Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Kidney Cancer treatment details. Biologic therapy. Immunotherapy. Christie Hospital NHS Trust, Manchester, United Kingdom

Survival: 19.7 months
Toxicity Grade: 3
Treatments: Biologic therapy
Country: United Kingdom
City/State/Province: Manchester
Hospital: Christie Hospital NHS Trust
Journal: Link
Date: 2/2007

Patients: This phase II study involved 43 patients with renal cell carcinoma. Of these patients, most (35) were men.

Treatment: All patients were treated with a 5T4 oncofoetal antigen tumour-targeted superantigen, ABR-214936. This therapy is a superantigen combined with an antibody against a molecule found on tumors. This superantigen stimulates the immune system and helps the antibody work.

Toxicity: Grade 3 hypotension was reported. The most common adverse events were pyrexia, rigour, lethargy/fatigue, nausea/vomiting, hypotension and hypertension.

Results: The median overall survival was 19.7 months. At the time this study was reported, 13 patients were alive.

Support: This study was supported by Active Biotech AB, the company that developed this therapeutic, which is also known as ANYARA.

Correspondence: Dr. DM Shaw

E-mail to a Friend Email Physician More Information